Improved access to R&D skills is needed; innovators need more ready access to scarce industry-class skills and expertise across project validation and critical-path R&D planning.
Without it, it can lead to inappropriate decisions that cause delays, damage the value of the drug candidates, and deliver low-value un-investible offerings to private sector funders.
We provide world-class expertise and know-how in drug discovery R&D to innovators. We assess and create high-quality critical path R&D programmes to deliver novel drug candidates.
